MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
4.750
+0.180
+3.94%
After Hours: 4.750 0 0.00% 16:10 07/07 EDT
OPEN
4.600
PREV CLOSE
4.570
HIGH
4.780
LOW
4.390
VOLUME
940.55K
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
1.290
MARKET CAP
301.92M
P/E (TTM)
-4.2727
1D
5D
1M
3M
1Y
5Y
1D
MacroGenics Completes Asset Sale, Shifts to R&D Focus
TipRanks · 15h ago
MacroGenics sells GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million
PUBT · 15h ago
Weekly Report: what happened at MGNX last week (0629-0703)?
Weekly Report · 2d ago
Bora Pharmaceuticals completes acquisition of MacroGenics biologics CDMO assets in Maryland
PUBT · 5d ago
MacroGenics sells GMP manufacturing operations to Bora for $122.5 million
PUBT · 5d ago
MACROGENICS COMPLETES SALE OF GMP MANUFACTURING OPERATIONS TO BORA PHARMACEUTICALS
Reuters · 5d ago
Weekly Report: what happened at MGNX last week (0622-0626)?
Weekly Report · 06/29 10:21
MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment
Seeking Alpha · 06/24 18:35
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.